DDIT3 and diffuse large B-cell lymphoma: Our results demonstrated that responders and non-responders of R-CHOP treatment had distinct 5hmC profiles and that 5hmC markers selected by bioinformatics tools and machine learning algorithms could be used to predict treatment response of R-CHOP treatment in DLBCL patients.